Copy the page URI to the clipboard
McLaurin, JoAnne; Kierstead, Meredith E.; Brown, Mary E.; Hawkes, Cheryl A.; Lambermon, Mark H. L.; Phinney, Amie L.; Darabie, Audrey A.; Cousins, Julian E.; French, Janet E.; Lan, Melissa F.; Chen, Fusheng; Wong, Sydney S.N.; Mount, Howard T. J.; Fraser, Paul E.; Westaway, David and St. George-Hyslop, Peter
(2006).
DOI: https://doi.org/10.1038/nm1423
Abstract
When given orally to a transgenic mouse model of Alzheimer disease, cyclohexanehexol stereoisomers inhibit aggregation of amyloid β peptide (Aβ) into high-molecular-weight oligomers in the brain and ameliorate several Alzheimer disease–like phenotypes in these mice, including impaired cognition, altered synaptic physiology, cerebral Aβ pathology and accelerated mortality. These therapeutic effects, which occur regardless of whether the compounds are given before or well after the onset of the Alzheimer disease–like phenotype, support the idea that the accumulation of Aβ oligomers has a central role in the pathogenesis of Alzheimer disease.